The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell lung cancer. METHODS: In this phase 2 trial, we evaluated the antitumor activity and safety of tarlatamab, administered intravenously every 2 weeks at a dose of 10 mg or 100 mg, in patients with previously treated small-cell lung cancer. The primary end point was objective response (complete or partial response), as assessed by blinded independent central review according to the Response Evaluation Criteria in Solid Tumors, version 1.1. RESULTS: Overall, 220 patients received tarlatamab; patients had previously received a median of two lines of treatment. Among patients evaluated for antitumor activity and survival, the median follow-up was 10.6 months in the 10-mg group and 10.3 months in the 100-mg group. An objective response occurred in 40% (97.5% confidence interval [CI], 29 to 52) of the patients in the 10-mg group and in 32% (97.5% CI, 21 to 44) of those in the 100-mg group. Among patients with an objective response, the duration of response was at least 6 months in 59% (40 of 68 patients). Objective responses at the time of data cutoff were ongoing in 22 of 40 patients (55%) in the 10-mg group and in 16 of 28 patients (57%) in the 100-mg group. The median progression-free survival was 4.9 months (95% CI, 2.9 to 6.7) in the 10-mg group and 3.9 months (95% CI, 2.6 to 4.4) in the 100-mg group; the estimates of overall survival at 9 months were 68% and 66% of patients, respectively. The most common adverse events were cytokine-release syndrome (in 51% of the patients in the 10-mg group and in 61% of those in the 100-mg group), decreased appetite (in 29% and 44%, respectively), and pyrexia (in 35% and 33%). Cytokine-release syndrome occurred primarily during treatment cycle 1, and events in most of the patients were grade 1 or 2 in severity. Grade 3 cytokine-release syndrome occurred less frequently in the 10-mg group (in 1% of the patients) than in the 100-mg group (in 6%). A low percentage of patients (3%) discontinued tarlatamab because of treatment-related adverse events. CONCLUSIONS: Tarlatamab, administered as a 10-mg dose every 2 weeks, showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell lung cancer. No new safety signals were identified. (Funded by Amgen; DeLLphi-301 ClinicalTrials.gov number, NCT05060016.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Self-citationPaz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32222-6 · Cited by 2,298
Self-citationvon Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., Stewart, D. J., Clark, P. I., Palmer, M. C., Depierre, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.658 · Cited by 968
Trigo, J., Subbiah, V., Besse, B., Moreno, V., López, R., Sala, M. A., Peters, S., Ponce, S., Fernández, C., Alfaro, V., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30068-1 · Cited by 486
Self-citationChung, H. C., Piha-Paul, S. A., Lopez-Martin, J., Schellens, J. H. M., Kao, S., Miller, W. H., Delord, J.-P., Gao, B., Planchard, D., Gottfried, M., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.109 · Cited by 408
Doyle, A., Martin, W. J., Funa, K., Gazdar, A., Carney, D., Martin, S. E., Linnoila, I., Cuttitta, F., Mulshine, J., & Bunn, P. (1985) · The Journal of experimental medicine · doi:10.1084/jem.161.5.1135 · Cited by 382
von Pawel, J., Jotte, R., Spigel, D. R., O'Brien, M. E. R., Socinski, M. A., Mezger, J., Steins, M., Bosquée, L., Bubis, J., Nackaerts, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5392 · Cited by 352
Self-citationThird-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Ready, N., Farago, A. F., de Braud, F., Atmaca, A., Hellmann, M. D., Schneider, J. G., Spigel, D. R., Moreno, V., Chau, I., Hann, C. L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.003 · Cited by 344
Paz-Ares, L., Champiat, S., Lai, W. V., Izumi, H., Govindan, R., Boyer, M., Hummel, H.-D., Borghaei, H., Johnson, M. L., Steeghs, N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02823 · Cited by 336
Self-citation
Cited by
The present and future of bispecific antibodies for cancer therapy
Klein, C., Brinkmann, U., Reichert, J. M., & Kontermann, R. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00896-6 · Cited by 490
A B7H3-targeting antibody–drug conjugate in advanced solid tumors: a phase 1/1b trial
Ma, Y., Yang, Y., Huang, Y., Fang, W., Xue, J., Meng, X., Fan, Y., Fu, S., Wu, L., Zheng, Y., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03600-2 · Cited by 122
Metadata
- Authors
- Ahn, M.-J., Cho, B. C., Felip, E., Korantzis, I., Ohashi, K., Majem, M., Juan-Vidal, O., Handzhiev, S., Izumi, H., Lee, J.-S., Dziadziuszko, R., Wolf, J., Blackhall, F., Reck, M., Bustamante Alvarez, J., Hummel, H.-D., Dingemans, A.-M. C., Sands, J., Akamatsu, H., Owonikoko, T. K., Ramalingam, S. S., Borghaei, H., Johnson, M. L., Huang, S., Mukherjee, S., Minocha, M., Jiang, T., Martinez, P., Anderson, E. S., & Paz-Ares, L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-11-30
- Volume
- 389
- Issue
- 22
- Pages
- 2063-2075
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4387799038
- Cited by
- 584
- References
- 16
- FWCI
- 60.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. https://app.cochat.ai/papers/10.1056/nejmoa2307980
- The paper
- Ahn, M.-J., Cho, B. C., Felip, E., Korantzis, I., Ohashi, K., Majem, M., Juan-Vidal, O., Handzhiev, S., Izumi, H., Lee, J.-S., Dziadziuszko, R., Wolf, J., Blackhall, F., Reck, M., Bustamante Alvarez, J., Hummel, H.-D., Dingemans, A.-M. C., Sands, J., Akamatsu, H., . . . Paz-Ares, L. (2023). Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2307980
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.